Comparative Pharmacology
Head-to-head clinical analysis: FREAMINE II 8 5 versus FREAMINE III 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FREAMINE II 8 5 versus FREAMINE III 10.
FREAMINE II 8.5% vs FREAMINE III 10%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FREAMINE II 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, supporting nitrogen balance and tissue repair in patients unable to tolerate oral or enteral nutrition.
FREAMINE III 10% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis and nitrogen balance in patients unable to tolerate oral or enteral nutrition.
Intravenous infusion: 0.8-1.5 g amino acids/kg/day. Typical dose is 500-1000 mL per day (42.5-85 g amino acids). Infusion rate should not exceed 0.1 g amino acids/kg/hour.
Intravenous administration as part of parenteral nutrition. Typical adult dose: 0.8-1.5 g amino acids/kg/day, infused continuously over 24 hours.
None Documented
None Documented
Not applicable as a mixture; individual amino acids have variable half-lives (e.g., essential amino acids ~1-3 hours). Clinical context: continuous infusion required to maintain plasma levels.
Component-dependent: free amino acids t1/2 ~15–30 min; urea cycle intermediates ca. 2 h.
Renal elimination of nitrogenous waste products (urea) derived from amino acid metabolism; <5% excreted unchanged in urine. No significant biliary or fecal elimination.
Primarily renal; amino acids and nitrogenous waste products are excreted as urea and other metabolites. <5% fecal.
Category C
Category C
Parenteral nutrition amino acid
Parenteral nutrition amino acid